Please assess the completion status of the following clinical trial:

Trial Title: Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient had a previous diagnosis of multiple myeloma~* Patient required retreatment for multiple myeloma~* Patient had measurable M component in serum or urine at study screening~Exclusion Criteria:~* Primary refractory disease (patients that never reached at least an minor response for over 60 days under any prior therapy)~* Patient who had been treated by bortezomib before, and did not reach at least a minor response under this therapy, or progressed under it or within 60 days of last dose~* Patient received prior treatment with DAC inhibitors including panobinostat~* Patient had impaired cardiac function, or a prolonged QTc interval at screening ECG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LBH589 + bortezomib + dexamethasone (Type: EXPERIMENTAL): Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.

Based on this trial design, predict the completion outcome and termination type (if applicable).